Exact Sciences (EXAS) Tops Q3 EPS by 5c; Raises FY Rev Outlook

Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.37), $0.05 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $118.3 million versus the consensus estimate of $109.31 million.

GUIDANCE:

Exact Sciences sees FY2018 revenue of $435-440 million, versus prior of $420-$430 million and the consensus of $428.75 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• RBC Capital Starts Tabcorp Holdings (TAH:AU) (TABCF) at Outperform
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)